TITLE

Long term suppressive therapy with pegylated interferon for chronic hepatitis C associated membranoproliferative glomerulonephritis

AUTHOR(S)
Cua, I. H. Y.; Kwon, V.; Henriquez, M.; Kench, J.; George, J.
PUB. DATE
October 2006
SOURCE
Gut;Oct2006, Vol. 55 Issue 10, p1521
SOURCE TYPE
Academic Journal
DOC. TYPE
Letter
ABSTRACT
The article presents a letter entitled "Long term suppressive therapy with pegylated interferon for chronic hepatitis C associated membranoproliferative glomerulonephritis" published within the issue. It focuses on the findings of the medical case involving a 46-year-old man with chronic hepatitis C virus infection and nephrotic syndrome. The patient underwent suppressive antiviral therapy with pegylated interferon.
ACCESSION #
22659603

 

Related Articles

  • Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in Hepatitis C virus replicon. Hazari, Sidhartha; Taylor, Lizeth; Haque, Salima; Garry, Robert F.; Florman, Sander; Luftig, Ronald; Regenstein, Frederic; Dash, Srikanta // Virology Journal;2007, Vol. 4, p89 

    Background: Alpha interferon in combination with ribavirin is the standard therapy for hepatitis C virus infection. Unfortunately, a significant number of patients fail to eradicate their infection with this regimen. The mechanisms of IFN-resistance are unclear. The aim of this study was to...

  • Antiviral Resistance and the Future Landscape of Hepatitis C Virus Infection Therapy. Wyles, David L. // Journal of Infectious Diseases;Mar2013, Vol. 207 Issue suppl_1, pS33 

    The addition of hepatitis C virus (HCV) protease inhibitors (PIs) to interferon and ribavirin therapy has significantly improved the efficacy of treatment for HCV infection. However, for patients who do not respond to therapy, the selection of HCV variants with resistance to PIs is likely....

  • Rapid Virologic Response: A New Milestone in the Management of Chronic Hepatitis C. Poordad, Fred; Reddy, K. Rajender; Martin, Paul // Clinical Infectious Diseases;1/1/2008, Vol. 46 Issue 1, p78 

    Background. Rapid virologic response (RVR), defined as an undetectable serum hepatitis C virus (HCV) RNA level at week 4 of treatment, is emerging as an important milestone in the treatment of patients who have chronic hepatitis C by use of pegylated interferon-alfa and ribavirin—the...

  • Hepatitis C Virus Envelope Glycoprotein Signatures Are Associated With Treatment Failure and Modulation of Viral Entry and Neutralization. Schvoerer, Evelyne; Moenne-Loccoz, Rémy; Murray, John M.; Velay, Aurélie; Turek, Marine; Fofana, Isabel; Fafi-Kremer, Samira; Erba, Anne-Claire; Habersetzer, François; Doffoël, Michel; Gut, Jean-Pierre; Donlin, Maureen J.; Tavis, John E.; Zeisel, Mirjam B.; Stoll-Keller, Françoise; Baumert, Thomas F. // Journal of Infectious Diseases;Apr2013, Vol. 207 Issue 8, p1306 

    Background. A major challenge for antiviral treatment of hepatitis C virus (HCV) infection is viral resistance, potentially resulting from the high variability of HCV envelope glycoproteins and subsequent selection of strains with enhanced infectivity and/or immune escape.Methods. We used a...

  • Challenges in the Management of HIV and Hepatitis C Virus Co-infection. Lee, Winston; Dieterich, Douglas // Drugs;2004, Vol. 64 Issue 7, p693 

    Hepatitis C virus (HCV) has become a significant contributor to morbidity and mortality to those infected with HIV since the introduction of highly active antiretroviral therapy (HAART). The presence of HIV clearly has a negative effect on the natural history of HCV, although there is some...

  • Peginterferon-α/ribavirin.  // Reactions Weekly;8/16/2008, Issue 1215, p33 

    The article describes the case of a de novo autoimmune hepatitis following successful combination anti-viral for recurrent hepatitis C virus liver disease. It references a study by A. D. Smith et al, published in the July 2008 issue of the "Liver Transplantation" journal. Also noted is the...

  • Effects of pegylated interferon α-2a on hepatitis-C-virus-associated glomerulonephritis. Sugiura, Tokio; Yamada, Takuji; Kimpara, Yuri; Fujita, Naoya; Goto, Kenji; Koyama, Norihisa // Pediatric Nephrology;Jan2009, Vol. 24 Issue 1, p199 

    Hepatitis C virus (HCV) infection leads to chronic liver disease, but it has also been associated with extrahepatic manifestations. Membranoproliferative glomerulonephritis (MPGN) is the most common renal disease associated with HCV. Although renal disease related to HCV in adults has been well...

  • Effect of interferon-alpha-based antiviral therapy on hepatitis C virus-associated glomerulonephritis: a meta-analysis. Feng, Bo; Eknoyan, Garabed; Guo, Zhong-sheng; Jadoul, Michel; Rao, Hui-ying; Zhang, Wei; Wei, Lai // Nephrology Dialysis Transplantation;Jan2012, Vol. 27 Issue 2, p640 

    Background. Hepatitis C virus (HCV) is associated with various glomerulopathies, in which HCV is responsible not only for the onset of glomerulopathy but also for its progressive loss of kidney function. The effect of antiviral treatment on the glomerular lesions and subsequent course of kidney...

  • Hepatitis C Virus, Cryoglobulinemia, and Kidney: Novel Evidence. Fabrizi, Fabrizio // Scientifica;2012, p1 

    Hepatitis C virus infection can lead to chronic active hepatitis, cirrhosis, and liver failure; however, it is also associated with a wide range of extra-hepatic complications. HCV is associated with a large spectrum of histopathological lesions in both native and transplanted kidneys, and it is...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics